Skip to main content
Premium Trial:

Request an Annual Quote

Signature BioScience Names New CSO, Finance Director

NEW YORK, May 1 – Protein structure determination company Signature BioScience said Tuesday it had appointed David Spellmeyer chief scientific officer and vice president of drug discovery.

Spellmeyer will be in charge of developing Signature BioScience’s new drug discovery efforts and validating the company’s technology.

Previously Spellmeyer was executive director at DuPont Pharmaceuticals Research Laboratories, where he oversaw the computational chemistry aspects of drug discovery and information technologies.

The San Francisco-based company also named Nancy Pecota senior director of finance and administration. Pecota was recently director of finance and accounting at Aclara BioSciences, where she was part of the management team that successfully took the company public.

Signature BioScience, an early stage proteomics company, has adapted telecommunications and computer chip technology to determine the structure and homology of classes of proteins.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.